Allarity Therapeutics News - ALLR

Company Name	Stock Ticker Symbol	Market	Type
Allarity Therapeutics Inc	ALLR	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	0.00	0.00%	1.42	19:59:42

Open Price	Low Price	High Price	Close Price	Prev Close
1.40	1.36	1.4499	1.37	1.42

more quote information »

Recent News

Date	Time	Source	Heading
4/17/2024	09:10	GLOBE	Allarity Therapeutics Receives NASDAQ-Approved Extension to..
4/04/2024	09:15	GLOBE	Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
3/27/2024	08:30	GLOBE	Allarity Therapeutics Makes Strategic Pivot to Focus Solely..
3/25/2024	07:30	GLOBE	Allarity Therapeutics Receives Extension from Nasdaq..
3/08/2024	08:38	EDGAR2	Form 8-K - Current report
3/08/2024	07:15	EDGAR2	Form 10-K - Annual report [Section 13 and 15(d), not S-K..
3/08/2024	07:15	GLOBE	Allarity Therapeutics Reports Full Year 2023 Financial..
3/07/2024	21:45	EDGAR2	Form DEF 14A - Other definitive proxy statements
3/04/2024	16:05	EDGAR2	Form 8-K - Current report
3/01/2024	09:21	EDGAR2	Form 8-K - Current report
2/28/2024	06:00	GLOBE	Allarity Therapeutics to Present at Biomarkers 2024
2/23/2024	16:09	EDGAR2	Form PRER14A - Preliminary Proxy Soliciting materials
2/14/2024	09:03	EDGAR2	Form 8-K - Current report
2/02/2024	17:03	EDGAR2	Form D - Notice of Exempt Offering of Securities
2/01/2024	16:40	EDGAR2	Form 8-K - Current report
1/26/2024	17:07	EDGAR2	Form PRE 14A - Other preliminary proxy statements
1/25/2024	17:24	EDGAR2	Form 8-K - Current report
1/19/2024	17:29	EDGAR2	Form 8-K - Current report
12/15/2023	17:00	EDGAR2	Form S-1/A - General form for registration of securities..
12/12/2023	06:00	GLOBE	Allarity Therapeutics Announces Thomas Jensen as Interim CEO..
12/11/2023	06:30	EDGAR2	Form 8-K - Current report
12/06/2023	17:00	EDGAR2	Form 8-K - Current report
12/06/2023	08:30	EDGAR2	Form S-1/A - General form for registration of securities..
12/05/2023	07:30	EDGAR2	Form 8-K - Current report
12/05/2023	07:30	GLOBE	Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical..
11/17/2023	17:01	EDGAR2	Form 8-K - Current report
11/13/2023	08:35	EDGAR2	Form 8-K - Current report
11/02/2023	17:00	EDGAR2	Form S-3 - Registration statement under Securities Act of..
10/31/2023	09:30	EDGAR2	Form S-1 - General form for registration of securities under..
10/30/2023	17:00	EDGAR2	Form 8-K - Current report
10/23/2023	17:01	EDGAR2	Form 424B3 - Prospectus [Rule 424(b)(3)]
10/17/2023	17:00	EDGAR2	Form S-3/A - Registration statement under Securities Act of..
10/10/2023	17:00	EDGAR2	Form S-3 - Registration statement under Securities Act of..
10/02/2023	07:00	GLOBE	Allarity Therapeutics to Present at Biomarkers Europe 2023
9/27/2023	16:30	EDGAR2	Form 8-K - Current report
9/15/2023	08:45	EDGAR2	Form 8-K - Current report
8/30/2023	16:05	GLOBE	PLOS ONE Publishes Data on Allarity Therapeutics’ DRP®..
8/14/2023	15:10	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
8/11/2023	08:15	EDGAR2	Form 8-K - Current report
7/31/2023	06:00	GLOBE	Allarity Therapeutics and FivepHusion Announce Collaboration..
7/27/2023	16:01	EDGAR2	Form 8-K - Current report
7/24/2023	06:00	GLOBE	Allarity Therapeutics Strengthens Board of Directors with..
7/17/2023	17:10	EDGAR2	Form 8-K - Current report
7/11/2023	16:05	EDGAR2	Form 8-K - Current report
7/07/2023	16:30	EDGAR2	Form 424B4 - Prospectus [Rule 424(b)(4)]
7/06/2023	06:05	EDGAR2	Form 8-K - Current report
7/06/2023	06:00	GLOBE	Allarity Therapeutics, Inc. Announces Pricing of $11 Million..
7/05/2023	16:31	EDGAR2	Form 8-K - Current report
7/05/2023	09:45	GLOBE	Initial Data from Allarity’s Phase 2 Trial of IXEMPRA®..
6/30/2023	17:23	EDGAR2	Form S-1/A - General form for registration of securities..